Confirm availability with customer service
This guide walks through the latest clinical evidence, including the 2025 SURMOUNT-5 head-to-head trial, so you can have an informed conversation with your provider
Many GLP1based plans use gradual dose increases to reduce nausea and stomach upset
Ohio to end GLP-1 drug weight loss coverage for state workers COLUMBUS, Ohio (WSYX) The Ohio Department of Administrative Services announced that coverage for GLP-1 drugs for weight loss, including Ozempic and Mounjaro, will end for state employees on July 1, 2025
Glutathione, often referred to as the "master antioxidant," is essential for combating oxidative stress, detoxifying harmful substances, and supporting immune function
Because these powerful drugs work on neural pathways in the brain to regulate appetite and satiety, questions have naturally been raised about their possible impact on mood, depression, and other serious psychiatric events, leaving many patients and clinicians searching for clear, evidence-based answers